NRWS yields 2000000.00% · ABBV yields 3.06%● Live data
📍 NRWS pulled ahead of the other in Year 1
Combined, NRWS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NRWS + ABBV for your $10,000?
Narrowstep Inc., along with its subsidiaries, offers Internet-based video content delivery services in Europe, Asia, and the United States. Its technology platform, TelvOS, enables the delivery of video content and television-like programming to mobile, wireless, the Internet, broadband, and broadcast services. The TelvOS system provides a platform to owners and users video content that enables to reach specific audiences by narrowcasting; and enables to commercialize video-based content through directed advertising, sponsorship, pay-per-view, subscription, and/or e-commerce. It also offers AdServer, an online system that enables the commercialization of broadband video distribution by providing the control and management of advertising content; PayGate, an interface between the TelvOS platform and payment gateways; NCoder, an encoding hardware solution that provides direct encoding capability for video content and attaches to a client's edit machine or network; and DownloadServer, a product integrated within TelvOS to offer downloads of various media. The company was incorporated in 2002 and is based in Princeton, New Jersey. It has an additional office in London, United Kingdom. Narrowstep Inc. operates as a subsidiary of Piksel Inc.
Full NRWS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.